Details of the Drug

General Information of Drug (ID: DM180DM)

Drug Name

ARGX-113

Indication

Disease Entry	ICD 11	Status	REF
Myasthenia gravis	8C6Y	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03770403) A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. (ADAPT+). U.S. National Institutes of Health.
2	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019 Jun 4;92(23):e2661-e2673.